Prestige Biopharma to Attend 'BIO USA 2026'... Aiming for Global Market Expansion

Prestige Biopharma will participate in the 'BIO International Convention 2026 (BIO USA 2026)', which will be held in San Diego, USA, from June 22 to 25.

According to Prestige Biopharma on June 16, the company plans to accelerate its two-track strategy at this event, focusing on global antibody drug partnering and expanding biosimilar commercialization. In the antibody drug sector, Prestige Biopharma will advance discussions on joint development and technology transfer for PBP1510 and PBP1710. PBP1510 is a first-in-class antibody drug that selectively targets PAUF, which is overexpressed in pancreatic cancer, and is currently being developed with the goal of entering Phase 2a clinical trials within this year. PBP1710 is an antibody drug candidate that targets CTHRC1, which is overexpressed in solid tumors, and is currently under development as part of the National New Drug Development Project.

In the biosimilar sector, the company will focus on advancing the North American entry and global commercialization of Avastin biosimilar 'VASFORDA® (HD204)' and selecting a North American partner for Herceptin biosimilar 'TUZNUE® (HD201)'. VASFORDA® (HD204) is currently undergoing preparations for regulatory approval and commercialization in the North American market. Prestige Biologics, which is responsible for manufacturing, is enhancing its production and quality systems to meet the standards of global regulatory agencies and facilitate approval reviews. Alongside preparations for North American approval, the company also plans to accelerate securing distribution and sales partners in additional countries.

The Prestige Biopharma Group plans to discuss joint development and commercialization strategies for subsequent pipeline products with global pharmaceutical and biotechnology companies, leveraging its integrated value chain that connects development, manufacturing, and commercialization. The company will also introduce its technology for switching antibody drugs to subcutaneous (SC) formulations and its AI-based research and development and biomanufacturing capabilities. Prestige Biopharma intends to share its AI competency in new drug target discovery, antibody optimization, bioprocessing, and quality prediction, as well as the current status of next-generation antibody delivery platform R&D, and explore potential collaborations with related companies.

This content was produced with the assistance of AI translation services.